Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

GlaxoSmithKline opened a new vaccines R&D center in Rockville, MD creating up to 200 new jobs.

GSK Opens Global Vaccines R&D Center in Maryland

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Principles of dissolution testing, including method development and testing apparatus, are reviewed.

Factors to Consider in Dissolution Testing

FDA and BARDA awarded a contract to Continuus Pharmaceuticals to develop an end-to-end continuous manufacturing process for solid-dosage drugs.

Continuus Pharmaceuticals Partners with FDA and BARDA

Quantitative and qualitative tools allow better understanding of mixing in a single-use bioprocessing system.

Evaluating Mixing in a Single-Use Bioprocessing System

Martin KÃ¶berle, PhD, is head of Analytical Development &Stability Testing, at Hermes Pharma.

Detlev Haack, PhD, is head of Research & Development at Hermes Pharma.

Hot-melt coating was used to develop taste-masked orally disintegrating granules of acetaminophen and caffeine.

From Bitter to Sweet: Developing a User-Friendly Painkiller

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Takeda Builds Dengue Vaccine Manufacturing Plant in Germany

Catalent adds two softgel facilities and packaging capabilities with acquisition of Canada-based Accucaps.

Catalent Expands Softgel Capacity with Accucaps Acquisition

Oxford Genetics has been awarded a grant to develop packaging cell lines for virus bioproduction and will work in collaboration with the University of Oxford to generate cell lines for the scalable manufacture of retrovirus and lentivirus vectors.

Oxford Genetics and University of Oxford Form Virus Production Pact

Avecia is adding drug substance capacity at its Milford, MA manufacturing site.

Nitto Avecia Expands Oligonucleotide Manufacturing Capacity

Research by agency scientists may help speed development of Zika virus vaccines.